Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over euro 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries.
Beutels
Philippe
P
Centre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp (Campus Drie Eiken), Universiteitsplein 1, 2610 Antwerp, Belgium. philippe.beutels@ua.ac.be
Thiry
Nancy
N
Van Damme
Pierre
P
D002675:Child, Preschool; D006801:Humans; D007223:Infant; D011008:Pneumococcal Infections / Q000191:economics / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination / Q000191:economics*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000191:economics
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate